FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tagThe FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain Share XFDA gives AbbVie’s c-Met lung cancer ADC a breakthrough taghttps://pharmaphorum.com/news/fda-gives-abbvies-c-met-lung-cancer-adc-a-breakthrough-tag/
FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tagDaiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) Share XFDA gives Daiichi Sankyo’s HER3 drug a breakthrough taghttps://pharmaphorum.com/news/fda-gives-daiichi-sankyos-her3-lung-cancer-drug-breakthrough-tag/
AZ, Daiichi take aim at Gilead in triple-negative breast cancerAstraZeneca and Daiichi Sankyo have reported new data with their antibody-drug conjugate for triple-negative breast cancer (TNBC), as Share XAZ, Daiichi take aim at Gilead in triple-negative breast cancerhttps://pharmaphorum.com/news/az-daiichi-take-aim-at-gilead-in-triple-negative-breast-cancer/
ASH abstract drop backs Roche’s Polivy in first-line lymphomaRoche trumpeted a top-line results of the POLARIX trial of its Polivy therapy in previously-untreated B-cell lymphoma, and Share XASH abstract drop backs Roche’s Polivy in first-line lymphomahttps://pharmaphorum.com/news/ash-abstract-drop-backs-roches-polivy-in-first-line-lymphoma/
AZ/Daiichi partner with Merck on first-line lung cancer trialThe dominance of Merck & Co’s Keytruda in the treatment of previously-untreated non-small cell lung cancer (NSCLC) means Share XAZ/Daiichi partner with Merck on first-line lung cancer trialhttps://pharmaphorum.com/news/az-daiichi-partner-with-merck-on-first-line-lung-cancer-trial/
HER2 heats up as Seagen licenses RemeGen ADC for $2.6bnSeagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate Share XHER2 heats up as Seagen licenses RemeGen ADC for $2.6bnhttps://pharmaphorum.com/news/her2-heats-up-as-seagen-licenses-remegen-adc-for-2-6bn/
Armed with phase 3 data, Roche preps filing for Polivy in first-line DLBCLRoche has the results it was hoping for in a phase 3 trial of Polivy in newly diagnosed Share XArmed with phase 3 data, Roche preps filing for Polivy in first-line DLBCLhttps://pharmaphorum.com/news/armed-with-ph3-trial-roche-preps-filing-for-polivy-in-first-line-dlbcl/
BMS pays $650m upfront for Eisai’s first ADC candidate for cancerJapan’s Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing Share XBMS pays $650m upfront for Eisai’s first ADC candidate for cancerhttps://pharmaphorum.com/news/bms-pays-650m-upfront-for-eisais-first-adc-candidate-for-cancer/
Ambrx tries another IPO as it chases down HER2 rivalsCalifornia biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Share XAmbrx tries another IPO as it chases down HER2 rivalshttps://pharmaphorum.com/news/ambrx-tries-another-ipo-as-it-chases-down-her2-rivals/
